Listing & Compliance Notices

Biotech Acquisition Co received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 9, 2023, Biotech Acquisition Company (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the Company’s failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. The Notice states that the Com”

Senior Connect Acquisition Corp. I received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 9, 2023, Senior Connect Acquisition Corp. I (the “Company”) received a notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company was deficient in meeting the requirements of Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders no later than one year after the end of the Company’s 2021 fiscal year-end. In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until February 23, 2023) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 ca”

CXApp Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 9, 2023, KINS Technology Group Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) stating that the Company failed to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2021, as required by Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until February 23, 2023) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 calendar days from its fiscal”

T3 Defense Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 9, 2023, Brilliant Acquisition Corporation (“Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”) which requires the Company to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securit”

Vinco Ventures, Inc. received a nasdaq deficiency notice notice regarding other.

“January 4, 2023, Vinco Ventures, Inc. (the “Company”) received a notification from Nasdaq that since it had not held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end ended December 31, 2021, it no longer complies with Nasdaq’s Listing Rules (the “Rules”) for continued listing. Under the Rules the Company has 45 calendar days to submit a plan to regain compliance and if the plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end, or until June 29, 2023, to regain compliance. The Company plans to submit”

American Virtual Cloud Technologies, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 6, 2023, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Listing Rule 5620(a), due to the Company’s failure to hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the NASDAQ Capital Market. The Notice states that the Company has until Febru”

SurgePays, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 5, 2023, SurgePays, Inc. (the “Company”), received a notification letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, since the Company has not yet held an annual meeting of shareholders within twelve months of the end of its December 31, 2021 fiscal year, it is out of compliance with the Nasdaq rules for continued listing (Listing Rules 5620(a) and 5810(c)(2)(G)). The notification letter has no immediate effect on the listing of the Company’s securities on the Nasdaq Capital Market. Under the applicable Nasdaq rules, the Company now”

SONIC FOUNDRY INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 6, 2023, Sonic Foundry, Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Common Stock on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180”

LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“January 11, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended November 27, 2022 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediat”

Edoc Acquisition Corp. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 5, 2023, Edoc Acquisition Corp. (the "Company") received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating the Company’s inability to hold its annual meeting of shareholders for the fiscal year ended December 31, 2021 (the “Annual Meeting”) pursuant to Nasdaq Listing Rule 5620(a) serves as an additional basis for delisting the Company’s securities from Nasdaq. The Company originally received a determination from the Staff on October 13, 2022 to delist the Company’s securities on grounds that the Company is not i”

Airspan Networks Holdings Inc. received a nyse_american delisting notice notice regarding other (rules 1001).

“January 6, 2023, the NYSE American provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Warrants and that the Warrants are no longer suitable for listing pursuant to Section 1001 of the NYSE American Company Guide due to the low trading price of the Warrants. To effect the delisting, the NYSE American will apply to the Securities and Exchange Commission (the “SEC”) to delist the Warrants pending completion of applicable procedures. The Company does not intend to appeal the NYSE American’s determination. The Comp”

OCA Acquisition Corp. received a nasdaq noncompliance notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 9, 2023, OCA Acquisition Corp. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) stating that the Company failed to hold an annual meeting of stockholders within 12 months after its fiscal year ended December 31, 2021, as required by Nasdaq Listing Rule 5620(a). In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until February 23, 2023) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up to 180 calendar days from its fiscal year”

FARADAY FUTURE INTELLIGENT ELECTRIC INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 31, 2022, relating to its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Deficiency”). The Notice has no immediate effect on the listing of the common stock on Nasdaq . The Company has 180 calendar days from October 31, 2022, or until May 1, 2023, to regain compliance with the minimum bid requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive tr”

FARADAY FUTURE INTELLIGENT ELECTRIC INC. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 4, 2023, Faraday Future Intelligent Electric Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) since the Company has not yet held an annual meeting of stockholders (the “Annual Meeting”) within 12 months of the Company’s fiscal year-end of December 31, 2021. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company may b”

Motus GI Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“January 4, 2023, the Company received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) which requires companies listed on Nasdaq to maintain a minimum $2,500,000 in stockholders’ equity for continued listing. The Company reported stockholders’ equity of $762,000 in its quarterly report on Form 10-Q for the period ended September 30, 2022, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). The Notice has no immediate impact on the listing of the Company’s common stock, which will cont”

Glucotrack, Inc. received a nasdaq noncompliance notice notice regarding shareholders.

“January 4, 2023, GlucoTrack, Inc. (the “Company”) received a notification from Nasdaq that since it had not held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end ended December 31, 2021, it no longer complies with our Listing Rules (the “Rules”) for continued listing. Under our Rules the Company has 45 calendar days to submit a plan to regain compliance and if plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the fiscal year end, or until June 29, 2023, to regain compliance. The Company has already submitted a plan”

Singularity Future Technology Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 5, 2023, Singularity Future Technology Ltd. (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, no par value (the “Common Stock”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market.”

UMPQUA HOLDINGS CORP received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 5, 2023, Umpqua received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market indicating that Umpqua was not in compliance with Listing Rule 5620(a) (the “Annual Shareholders Meeting Rule”), which requires Umpqua to hold an annual meeting of shareholders within 12 months of the end of Umpqua’s fiscal year ended December 31, 2021 for continued listing on the NASDAQ Global Select Market (the “Nasdaq”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of Umpqua”

Ainos, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 5, 2023, Ainos, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its comm”

REPUBLIC FIRST BANCORP INC received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“January 3, 2023, Republic First Bancorp, Inc. (the “Company”) received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Listing Rule 5620(a) (the “Rule”), which required the Company to hold an annual meeting of shareholders no later than one year after the end of the Company’s fiscal year-end for continued listing on The Nasdaq Global Market. As reported by the Company in its Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “Commission”) on November 10”

Enservco Corp received a nyse_american deficiency notice notice regarding other (rules 704).

“January 3, 2023, Enservco Corporation (the “Company”) received an official notice of noncompliance from the NYSE Regulation (“NYSE”) stating that the Company is noncompliant with Section 704 of the NYSE American Company Guide (the “Company Guide”) for failure to hold an annual meeting for the fiscal year ended December 31, 2021 by December 31, 2022 (“2021 Annual Meeting”). Section 704 of the Company Guide requires an issuer to hold an annual meeting during each fiscal year. The Company expects to hold its Annual Meeting in 2023, at which time the Company will regain compliance with NYSE Americ”

Peak Bio, Inc. received a nasdaq noncompliance notice notice regarding other (rules IM-5101-2, 5505(a)(2)).

“December 8, 2022 to appeal Nasdaq’s determination, which request stayed the suspension of the Company’s common stock and warrants and the filing by Nasdaq of a Form 25-NSE pending the Panel’s decision. On January 6, 2023, the Company received the determination letter (the “Determination Letter”) from the Panel to delist the Company’s common stock and warrants from Nasdaq. The Determination Letter indicated Nasdaq will suspend trading in Company’s common stock and warrants effective at the open of business on January 10, 2023 and indicated that it intends to file a Form 25-NSE Notification of D”

Polished.com Inc. received a nyse_american deficiency notice notice regarding other.

“January 3, 2023, NYSE American sent the Company a letter stating that the Company was not in compliance with Section 704 of the Company Guide. The Company plans to hold an annual meeting of stockholders on January 19, 2023, as indicated in the Definitive Proxy Statement on Schedule 14A the Company filed with the Securities Exchange Commission on December 19, 2022.”

Cherry Hill Mortgage Investment Corp received a nyse deficiency notice notice regarding audit committee (rules 303A.07(a), 303A.02).

“ees”) at the time of her passing. Following Ms. Lowrie’s death, the Board has been reduced to three members, two of whom are independent directors. The Committees have been reduced to two members, both of whom are independent directors. As a result, the Company is no longer compliant with Section 303A.07(a) of the New York Stock Exchange (“NYSE”) Listed Company Manual (the “Listed Company Manual”), which requires that the audit committee of an NYSE-listed company consist of at least three members, each of whom is an independent director. The Company notified the NYSE of Ms. Lowrie’s passing”

REGIONAL HEALTH PROPERTIES, INC received a nyse_american deficiency notice notice regarding other (rules 704).

“January 3, 2023 from NYSE American (the “Exchange”), wherein the Exchange advised that the Company is not in compliance with its continued listing standard set forth in Section 704 of the NYSE American Company Guide as the Company did not hold an annual meeting of shareholders for the fiscal year ended December 31, 2021 (the “2022 Annual Meeting”) by December 31, 2022. The Company has scheduled the 2022 Annual Meeting for February 14, 2023 at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia 30096, at 10:00 a.m. local time. The Company believes that once the 2”

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

“January 4, 2023, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2021 fiscal year end. The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company m”

ROGERS CORP received a nyse deficiency notice notice regarding other (rules 302).

“January 3, 2023, Rogers Corporation (the “Company”) received a written letter (the “Notice”) from the NYSE Regulation office of the New York Stock Exchange (“NYSE”), which provided notice that the Company is not in compliance with Section 302 of the NYSE Listed Company Manual due to the failure to hold an annual meeting during 2022. The failure to hold an annual meeting was due to the pendency of the Company’s proposed merger with DuPont de Nemours, Inc. (“DuPont”), which was announced on November 2, 2021 and was terminated by DuPont on November 1, 2022. Upon termination of the merger, the Com”

Jackson Acquisition Co received a nyse delisting notice notice regarding other (rules 802.01D).

“January 3, 2023, the New York Stock Exchange (the “ NYSE ”) notified Jackson Acquisition Company (the “ Company ”), and publicly announced, that the NYSE had determined that the Company’s warrants, each warrant exercisable for one share of Class A Common Stock of the Company (the “ Warrants ”), are no longer suitable for listing on the NYSE due to trading price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As a result, the NYSE has determined to commence proceedings to delist the Warrants from the NYSE. The Company has a right to a review of this determination by a C”

QualTek Services Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 5, 2023, the Company received a letter (the “ Minimum Bid Price Notice ”) from the Staff notifying the Company that its Class A common stock, $0.0001 par value per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Rule ”) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. The Minimum Bid Price Notice has no immediate effect on the listing of the Common Stock”

EdtechX Holdings Acquisition Corp. II received a nasdaq noncompliance notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 3, 2023, the Company received a notice (the “Nasdaq Notice”) from the Listing Qualifications Department of Nasdaq stating that, as of December 27, 2022, the Company had failed to hold the above-referenced annual meeting and therefore was not in compliance with the Rule. As a result, the Listing Qualifications Department has advised the Company that its securities would be subject to delisting unless the Company timely requests a hearing before an independent Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing. The hearing request will stay any sus”

micromobility.com Inc. received a nasdaq deficiency notice notice regarding other (rules 5260(a)).

“January 4, 2023, we received written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) stating that Nasdaq determined we were not in compliance with Nasdaq Listing Rule 5260(a) due to our failure to hold an annual meeting of the shareholders within the twelve months following our fiscal year ended December 31, 2021 (the “Annual Meeting”). The Notice has no immediate effect on the listing of our Class A common stock (symbol: HLBZ) or our warrants to purchase shares of Class A common stock (symbol: HLBZW) on the Nasdaq Capital Market. The”

Finch Therapeutics Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2022, Finch Therapeutics Group, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $ 0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The deficiency letter has no immediate effect on the”

Exela Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).

“January 5, 2023, the Company received notice from the Staff that the Staff had determined that as of January 4, 2023, the Company’s securities had a closing bid price of $0.10 or less for eleven consecutive trading days triggering application of Listing Rule 5810(c)(3)(A)(iii) which states in part: if during any compliance period specified in Rule 5810(c)(3)(A) a Company’s security has a closing bid price of $0.10 or less for ten consecutive trading days, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810 with respect to that security. As a resul”

Corbus Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 4, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to”

Jaguar Health, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(3)(A)(iii)).

“January 5, 2023, Jaguar Health, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the bid price for the Company’s voting common stock, par value $0.0001 per share (the “Common Stock”), had closed below $0.10 per share for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(3)(A)(iii) (the “$0.10 Rule”), the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appea”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 4, 2023, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) for the last 30 consecutive business days, the Common Stock did not meet the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2), initiating an automatic 180 calendar-day grace period for the Company to regain compliance. The notice has no immediate effect on the listing or trading of the Company”

Mobiquity Technologies, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 4, 2023, we received a deficiency notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of its noncompliance with the Nasdaq Listing Rule 5620(a) to hold an annual meeting of shareholders within no later than one year after the end of the Company’s fiscal year end. Under Nasdaq Rules the Company now has 45 calendar days to submit a plan to regain compliance and can grant up to 180 calendar days from the fiscal year end, or until June 29, 2023, to regain compliance. SIGNATURES Pursuant to the requirements of the Securitie”

Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“January 3, 2023, the Company received a letter from the Staff notifying it that, as of December 30, 2022, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days during the Minimum Bid Price Rule Compliance Period and, therefore, as contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Company’s common stock will be delisted from The Nasdaq Capital Market. Nasdaq indicated that it would suspend trading in the Company’s common stock at the opening of business on January 12, 2023 and file a Form 25-NSE with the Securities and Exchange Commiss”

Panbela Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 19, 2022, Panbela Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Company submitted to Nasdaq a plan to regain compliance with the Minimum Equity Rule and was grant”

SUNPOWER CORP received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)).

“January 4, 2023 that, as a result of Ms. Lesjak’s resignation, the Company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2), as described above. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUNPOWER CORPORATION January 5, 2023 By: /S/ EILEEN EVANS Name: Eileen Evans Title: Executive Vice President and Chief Legal Officer”

Surrozen, Inc./DE received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 4, 2023, Surrozen, Inc. received a written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that on January 3, 2023, the average closing price of our common stock over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days to regain compliance with the Minimum Bid Requirement (the “Grace Period”), subject t”

Jounce Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 29, 2022, Jounce Therapeutics, Inc., a Delaware corporation (the “Company”), received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with N”

Neptune Wellness Solutions Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“December 29, 2022, Neptune Wellness Solutions Inc. (the “Company”) received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires that the closing bid price for the Company's common shares listed on Nasdaq be maintained at a minimum of $1.00. Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines”

NextPlat Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 5, 2023, we received notice from The Nasdaq Stock Market, Inc. (“Nasdaq”) that we are out of compliance with the Nasdaq rules for continued listing (Listing Rules 5620(a) and 5810(c)(2)(G)) as a result of our failure to hold an annual meeting of shareholders within twelve months of the end of our fiscal year ended December 31, 2021. Under the applicable Nasdaq rules, we now have 45 calendar days to submit a plan to regain compliance. We intend to submit a plan of compliance in response to the notice. If Nasdaq accepts our plan of compliance, we may be granted an exception of up to 180”

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“November 22, 2022 stating that the Company’s stockholders’ equity of approximately $8.8 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, fails to comply with the minimum $10.0 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(1)(A). The Notice provided that the Company may consider applying to transfer the listing of the Company’s common stock, par value $0.005 per share (the “ common stock ”) to The Nasdaq Capital Market, subject to the Compan”

Starry Group Holdings, Inc. received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).

“December 14, 2022, the New York Stock Exchange (the “NYSE”) notified Starry Group Holdings, Inc. (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”) and warrants to purchase shares of Class A Common Stock (the “Warrants”) from the NYSE and that trading in the Class A Common Stock and Warrants would be suspended immediately, due to trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Following suspension of trading on the NYS”

Hudson Acquisition I Corp. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“December 27, 2022, the Company received a compliance letter from Nasdaq (the “Compliance Letter”) stating that based on the Company’s filing of the 10-Q on December 21, 2022, Nasdaq has determined that the Company is in compliance with the Listing Rule and has accordingly closed the delinquency matter.”

Axcella Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2022, Axcella Health Inc. (the “Company” or “Axcella”), doing business as “Axcella Therapeutics,” received a letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business day period between November 16, 2022 through December 29, 2022, the Company’s common stock had not maintained a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”) required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). The Nasdaq letter”

Boxlight Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“January 3, 2023, the Company received formal approval from Nasdaq granting it an additional 180 days, or until July 3, 2023 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If at any time before the Compliance Date the closing bid price for the Company’s Common Stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation of compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Staff will provide written notifica”

KUSTOM ENTERTAINMENT, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 4, 2023, Nasdaq approved the Company’s request for a second 180-day period, or until July 3, 2023, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period(s), including any further extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting from the Nasdaq Capital Market. The Company intends to continuously monitor the closing bid price for its Common Stock and is in the process of considering various measures to resolve the deficiency and reg”